At a ceremony last Friday at BIO Japan in Yokohama, the BIA and the Japanese Forum for Innovative Regenerative Medicine (FIRM) exchanged directories of our members operating in the Cell and Gene Therapy space. This exciting new business tool springs from a partnership that was cemented with the signing of a Memorandum of Understanding between the BIA and FIRM earlier in the year. On our side, the work is led by the Cell and Gene Therapy Advisory Committee (CGTAC).
The last decade has seen significant scientific developments in cell therapies, gene therapies and tissue engineered products, collectively described as ATMPs (Advanced Therapy Medicinal Products). The impact of such treatments could be transformational. As such, we believe it is crucially important to support the sector as it navigates the complex clinical, regulatory, manufacturing, and pricing environments in which it operates.
The BIA’s 16th Annual bioProcess UK Conference will be held in Liverpool on the 27-28 November! We will welcome delegates to a city renowned for its culture and arts, as well as being the home to Liverpool Football Club, the current Champions League and Super Cup winners.
The Science Industry Partnership (SIP) in collaboration with BIA, ABPI and with the support of the Office for Life Sciences (OLS) can now report on the interim findings of the Life Sciences 2030 Skills Strategy which is building a clear evidence base of the status of life science skills and future scenarios to 2030.
Last week hidden beneath the Government's announcement that students will be able to stay in the UK for two years, there were developments on the UK life science industrial strategy, which the BIA has partnered with government on for the last three years.